Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Benztropine
Drug ID BADD_D00244
Description Benztropine, with the chemical formula 3alpha-diphenylmethoxytropane, is a tropane-based dopamine inhibitor used for the symptomatic treatment of Parkinson's disease. It is a combination molecule between a tropane ring, similar to cocaine, and a diphenyl ether from the dialkylpiperazines determined to be a dopamine uptake inhibitor since 1970. The generation of structure-activity relationships proved that benztropine derivatives with the presence of a chlorine substituent in the para position in one of the phenyl rings produces an increased potency for dopamine uptake inhibition as well as a decreased inhibition of serotonin and norepinephrine.[A37914] Benztropine was developed by USL Pharma and officially approved by the FDA on 1996.[L5500]
Indications and Usage Benztropine is indicated to be used as an adjunct in the therapy of all forms of parkinsonism. It can also be used for the control of extrapyramidal disorders due to neuroleptic drugs.[T203] The extrapyramidal symptoms are defined as drug-induced disorders that include symptoms of dystonia, akathisia, parkinsonism, bradykinesia, tremors, and dyskinesia.[A175120] Parkinsonism is a general term that refers to the group of neurological disorders that produce symptoms similar to Parkinson's disease such as tremors, slow movement, and stiffness. The parkinsonism includes a large number of disorders and some of them have not been clearly defined.[L5509]
Marketing Status approved
ATC Code N04AC01
DrugBank ID DB00245
KEGG ID D07511
MeSH ID D001590
PubChem ID 1201549
TTD Drug ID D0HQ6N
NDC Product Code 69097-826; 69097-827; 69097-832
UNII 1NHL2J4X8K
Synonyms Benztropine | Benzatropine | Bensylate | Benzatropine Methanesulfonate | Methanesulfonate, Benzatropine | Benzatropine Mesylate | Mesylate, Benzatropine | Benztropine Mesylate | Mesylate, Benztropine | Benzatropine Methanesulfonate, Hydrobromide | Hydrobromide Benzatropine Methanesulfonate | Methanesulfonate, Hydrobromide Benzatropine | PMS-Benztropine | PMS Benztropine | Benzatropine Methanesulfonate, Hydrochloride, (endo)-Isomer | Cogentin | Cogentinol | N-Methylbenztropine | N Methylbenztropine | Apo-Benztropine | Apo Benztropine | Benzatropine Methanesulfonate, Hydrobromide, (endo)-Isomer
Chemical Information
Molecular Formula C21H25NO
CAS Registry Number 86-13-5
SMILES CN1C2CCC1CC(C2)OC(C3=CC=CC=C3)C4=CC=CC=C4
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Injection site reaction12.07.03.015; 08.02.03.014--
Listless19.04.04.003; 08.01.01.012--Not Available
Memory impairment19.20.01.003; 17.03.02.0030.000737%
Muscle twitching15.05.03.005--Not Available
Mydriasis17.02.11.003; 06.05.03.004--Not Available
Nasal congestion22.04.04.001--
Nausea07.01.07.001--
Nervousness19.06.02.003--Not Available
Neuroleptic malignant syndrome15.05.04.015; 12.03.01.003; 08.05.01.005; 17.05.02.0030.000410%Not Available
Oedema08.01.07.006; 14.05.06.010--Not Available
Pyrexia08.05.02.003--
Rash23.03.13.001--Not Available
Rash maculo-papular23.03.13.004--
Schizophrenia19.03.04.0010.000410%Not Available
Somnolence19.02.05.003; 17.02.04.006--
Speech disorder22.12.03.027; 19.19.02.002; 17.02.08.003--Not Available
Suicide attempt19.12.01.0040.000273%
Tachycardia02.03.02.007--Not Available
Tremor17.01.06.002--
Urinary retention20.02.02.0110.000874%
Vision blurred06.02.06.007; 17.17.01.0100.001393%
Visual impairment06.02.10.013--Not Available
Vomiting07.01.07.003--
Weight decreased13.15.01.005--
Mental status changes19.07.01.0010.000737%Not Available
Abnormal behaviour19.01.01.0010.000601%Not Available
Decreased appetite14.03.01.005; 08.01.09.028--
Psychotic disorder19.03.01.002--
The 2th Page    First    Pre   2    Total 2 Pages